Role of IL-26+CD26+CD4 T Cells in Pulmonary Chronic Graft-Versus-Host Disease and Treatment with Caveolin-1-Ig Fc Conjugate

Crit Rev Immunol. 2016;36(3):239-267. doi: 10.1615/CritRevImmunol.2016018772.

Abstract

Obliterative bronchiolitis is the primary noninfectious pulmonary complication after allogeneic hematopoietic cell transplantation and the only pathognomonic manifestation of pulmonary chronic graft-versus-host disease (cGVHD). In our recent study, we identified a novel effect of IL-26, which is absent in rodents, on transplant related-obliterative bronchiolitis. Sublethally irradiated NOD/Shi-scidIL2rγnull mice transplanted with human umbilical cord blood gradually exhibited obliterative bronchiolitis with increased collagen deposition and predominant infiltration with human IL-26+CD26+CD4 T cells. Moreover, we showed that IL-26 increased collagen synthesis in fibroblasts in vitro and that collagen contents were increased in a murine GVHD model using IL26 transgenic mice. In vitro analysis demonstrated a significant increase in IL-26 production by CD4 T cells following CD26 costimulation, while immunoglobulin Fc domain fused with the N-terminal of caveolin-1, the ligand for CD26, (Cav-Ig) effectively inhibited production of IL-26. Administration of Cav-Ig before or after onset of GVHD impeded the development of clinical and histologic features of GVHD without interrupting engraftment of donor-derived human cells, with preservation of the graft-versus-leukemia effect. We concluded that cGVHD of the lungs is caused in part by IL-26+CD26+CD4 T cells, and that treatment with Cav-Ig could be beneficial for cGVHD prevention and therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Bronchiolitis Obliterans / etiology
  • Bronchiolitis Obliterans / therapy*
  • CD4-Positive T-Lymphocytes / physiology*
  • Caveolin 1 / therapeutic use*
  • Chronic Disease
  • Dipeptidyl Peptidase 4 / physiology*
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / therapy*
  • Humans
  • Interleukins / physiology*
  • Mice
  • Recombinant Fusion Proteins / therapeutic use*

Substances

  • Caveolin 1
  • IL26 protein, human
  • Interleukins
  • Recombinant Fusion Proteins
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4